title: Amplification of the 9p13.3 chromosomal region in prostate cancer.
abstract: Amplification of the 9p13.3 chromosomal region occurs in a subset of prostate cancers (PCs); however, the target gene or genes of this amplification have remained unidentified. The aim of this study was to investigate the 9p13.3 amplification in more detail to identify genes that are potentially advantageous for cancer cells. We narrowed down the minimally amplified area and assessed the frequency of the 9p13.3 amplification. Of the clinical samples from untreated PCs that were examined (n = 134), 9.7% showed high-level amplification, and 32.1% showed low-level amplification. Additionally, in clinical samples from castration-resistant PCs (n = 70), high- and low-level amplification was seen in 14.3% and 44.3% of the samples, respectively. We next analyzed the protein-coding genes in this chromosomal region for both their expression in clinical PC samples as well as their potential as growth regulators in PC cells. We found that the 9p13.3 amplification harbors several genes that are able to affect the growth of PC cells when downregulated using siRNA. Of these, UBAP2 was the most prominently upregulated gene in the clinical prostate tumor samples. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Institute of Biosciences and Medical Technology - BioMediTech, University of Tampere, Finland.|Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
authors.forename: Leena
authors.initials: L
authors.lastname: Latonen
authors.affiliation: Institute of Biosciences and Medical Technology - BioMediTech, University of Tampere, Finland.|Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
authors.forename: Katri A
authors.initials: KA
authors.lastname: Leinonen
authors.affiliation: Institute of Biosciences and Medical Technology - BioMediTech, University of Tampere, Finland.|Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
authors.forename: Teemu
authors.initials: T
authors.lastname: Grönlund
authors.affiliation: Department of Urology, University of Washington, Seattle, WA.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Vessella
authors.affiliation: Department of Urology, University of Tampere and Tampere University Hospital, Tampere, Finland.
authors.forename: Teuvo L J
authors.initials: TL
authors.lastname: Tammela
authors.affiliation: Institute of Biosciences and Medical Technology - BioMediTech, University of Tampere, Finland.|Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
authors.forename: Outi R
authors.initials: OR
authors.lastname: Saramäki
authors.affiliation: Institute of Biosciences and Medical Technology - BioMediTech, University of Tampere, Finland.|Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
authors.forename: Tapio
authors.initials: T
authors.lastname: Visakorpi
mesh_terms: D000368:Aged; D000818:Animals; D002352:Carrier Proteins / Q000235:genetics*; D045744:Cell Line, Tumor; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics*; D018572:Disease-Free Survival; D005784:Gene Amplification / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D051379:Mice; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology; D064129:Prostatic Neoplasms, Castration-Resistant / Q000235:genetics* / Q000473:pathology; D023041:Xenograft Model Antitumor Assays
chemical_list: D002352:Carrier Proteins